Compare Cytokinetics Inc (CYTK) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Global Payments Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Global Payments Inc trades at $82.2 (market cap $21.46B). The key difference: Global Payments Inc is far larger — about 2.5× Cytokinetics Inc's market cap, and Global Payments Inc pays a 1.23% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Global Payments Inc for 50 Days on average.
| CYTK | GPN | |
|---|---|---|
Market Cap | $8.62B | $21.46B |
Volume | 2,594,626 | 1,482,600 |
Sector | Health | Financials |
52-Week High | $87.26 | $94.83 |
52-Week Low | $54.76 | $62.47 |
Typical Hold Time | 19 Days | 50 Days |
Enterprise Value | $8.72B | $39.60B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Global Payments (GPN) trades at $82.77, up 2.08% with neutral technical signals and bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though 2026 projections indicate potential profitability challenges. Recent developments include the Genius platform expansion and Worldpay integration driving growth opportunities, while elevated debt levels and competitive pressures present headwinds.
The stock offers 24% upside to the $102.75 consensus target with strong analyst support (59% buy ratings), but investors face risks from declining 2026 profitability projections and rising debt-to-asset ratios. The company's digital payment initiatives provide growth catalysts, though execution risks and margin pressures require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
